| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8721315 | Clinical Immunology | 2018 | 21 Pages |
Abstract
By decreasing the rate of infections, the prophylactic administration of SCIg improves both adherence to chemotherapy and health-related quality of life, and is cost-effective by reducing the need of hospitalization and the use of antibiotics.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Angelo Vacca, Assunta Melaccio, Azzurra Sportelli, Antonio G. Solimando, Franco Dammacco, Roberto Ria,